IL294710A - Bacteria engineered to treat disorders in which oxalate is detrimental - Google Patents
Bacteria engineered to treat disorders in which oxalate is detrimentalInfo
- Publication number
- IL294710A IL294710A IL294710A IL29471022A IL294710A IL 294710 A IL294710 A IL 294710A IL 294710 A IL294710 A IL 294710A IL 29471022 A IL29471022 A IL 29471022A IL 294710 A IL294710 A IL 294710A
- Authority
- IL
- Israel
- Prior art keywords
- oxalate
- gene
- encoding
- sequence
- promoter
- Prior art date
Links
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 title claims description 842
- 241000894006 Bacteria Species 0.000 title claims description 352
- 230000009931 harmful effect Effects 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 858
- 230000015556 catabolic process Effects 0.000 claims description 335
- 108090000790 Enzymes Proteins 0.000 claims description 285
- 102000004190 Enzymes Human genes 0.000 claims description 276
- 230000001939 inductive effect Effects 0.000 claims description 132
- 238000000034 method Methods 0.000 claims description 106
- 208000008852 Hyperoxaluria Diseases 0.000 claims description 68
- 241000588724 Escherichia coli Species 0.000 claims description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 37
- 101150100470 frc gene Proteins 0.000 claims description 23
- 230000002485 urinary effect Effects 0.000 claims description 21
- 230000037430 deletion Effects 0.000 claims description 20
- 238000012217 deletion Methods 0.000 claims description 20
- 230000001154 acute effect Effects 0.000 claims description 17
- 230000007423 decrease Effects 0.000 claims description 14
- 208000004777 Primary Hyperoxaluria Diseases 0.000 claims description 13
- 230000003115 biocidal effect Effects 0.000 claims description 10
- 235000012054 meals Nutrition 0.000 claims description 10
- 241000588722 Escherichia Species 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 210000001072 colon Anatomy 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 4
- 230000000378 dietary effect Effects 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 4
- 101150083575 oxdC gene Proteins 0.000 claims description 4
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010033649 Pancreatitis chronic Diseases 0.000 claims description 3
- 206010049416 Short-bowel syndrome Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 101150001227 oxlT gene Proteins 0.000 claims description 3
- 108060006698 EGF receptor Proteins 0.000 claims description 2
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims description 2
- 229960004770 esomeprazole Drugs 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 2
- 239000000612 proton pump inhibitor Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 363
- 230000001580 bacterial effect Effects 0.000 description 349
- 229940088598 enzyme Drugs 0.000 description 274
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 179
- 108090000765 processed proteins & peptides Proteins 0.000 description 178
- 102000004196 processed proteins & peptides Human genes 0.000 description 156
- 229920001184 polypeptide Polymers 0.000 description 147
- 108010078791 Carrier Proteins Proteins 0.000 description 141
- 230000001105 regulatory effect Effects 0.000 description 101
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 81
- 230000014509 gene expression Effects 0.000 description 74
- 210000001035 gastrointestinal tract Anatomy 0.000 description 66
- 102000004169 proteins and genes Human genes 0.000 description 64
- 239000013612 plasmid Substances 0.000 description 63
- 239000001301 oxygen Substances 0.000 description 62
- 229910052760 oxygen Inorganic materials 0.000 description 62
- 241000605936 Oxalobacter formigenes Species 0.000 description 59
- 235000018102 proteins Nutrition 0.000 description 59
- 239000007845 reactive nitrogen species Substances 0.000 description 59
- 101710189384 Oxalate:formate antiporter Proteins 0.000 description 56
- 108091023040 Transcription factor Proteins 0.000 description 46
- 102000040945 Transcription factor Human genes 0.000 description 46
- 208000035475 disorder Diseases 0.000 description 42
- 230000007613 environmental effect Effects 0.000 description 41
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 40
- 235000001014 amino acid Nutrition 0.000 description 38
- 239000012634 fragment Substances 0.000 description 38
- 230000008676 import Effects 0.000 description 38
- 210000000349 chromosome Anatomy 0.000 description 37
- 201000010099 disease Diseases 0.000 description 36
- 244000005700 microbiome Species 0.000 description 36
- 230000001627 detrimental effect Effects 0.000 description 33
- 230000035772 mutation Effects 0.000 description 33
- 229940024606 amino acid Drugs 0.000 description 31
- 150000001413 amino acids Chemical class 0.000 description 31
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 30
- 125000003275 alpha amino acid group Chemical group 0.000 description 30
- 230000001965 increasing effect Effects 0.000 description 30
- 150000007523 nucleic acids Chemical group 0.000 description 29
- 241000894007 species Species 0.000 description 29
- 101150013175 oxc gene Proteins 0.000 description 28
- 230000002103 transcriptional effect Effects 0.000 description 28
- 230000032258 transport Effects 0.000 description 28
- 108091026890 Coding region Proteins 0.000 description 26
- QVXMZFTWJVBUHP-IBOSZNHHSA-N oxalyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QVXMZFTWJVBUHP-IBOSZNHHSA-N 0.000 description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 description 22
- 239000002207 metabolite Substances 0.000 description 22
- 235000006408 oxalic acid Nutrition 0.000 description 22
- 102000003669 Antiporters Human genes 0.000 description 21
- 108090000084 Antiporters Proteins 0.000 description 21
- 230000001419 dependent effect Effects 0.000 description 21
- 230000028327 secretion Effects 0.000 description 21
- -1 DNA Chemical class 0.000 description 20
- 230000027455 binding Effects 0.000 description 20
- 238000012239 gene modification Methods 0.000 description 20
- 230000005017 genetic modification Effects 0.000 description 20
- 235000013617 genetically modified food Nutrition 0.000 description 20
- 230000004968 inflammatory condition Effects 0.000 description 19
- 108010032737 oxalyl CoA decarboxylase Proteins 0.000 description 18
- 238000006467 substitution reaction Methods 0.000 description 16
- 239000001569 carbon dioxide Substances 0.000 description 15
- 229910002092 carbon dioxide Inorganic materials 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 230000004700 cellular uptake Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- 230000000670 limiting effect Effects 0.000 description 13
- 239000006041 probiotic Substances 0.000 description 12
- 235000018291 probiotics Nutrition 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 11
- 208000000897 Primary hyperoxaluria type 2 Diseases 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 230000000529 probiotic effect Effects 0.000 description 11
- 241000193403 Clostridium Species 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 10
- 241000186660 Lactobacillus Species 0.000 description 10
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 10
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 208000000891 primary hyperoxaluria type 1 Diseases 0.000 description 10
- 241000186000 Bifidobacterium Species 0.000 description 9
- 240000001046 Lactobacillus acidophilus Species 0.000 description 9
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 9
- 101710199606 Oxalate-CoA ligase Proteins 0.000 description 9
- 108030005803 Oxalate-CoA ligases Proteins 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 244000052616 bacterial pathogen Species 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 229940039696 lactobacillus Drugs 0.000 description 9
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 9
- 239000003053 toxin Substances 0.000 description 9
- 231100000765 toxin Toxicity 0.000 description 9
- 108700012359 toxins Proteins 0.000 description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 8
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 8
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 8
- 240000006024 Lactobacillus plantarum Species 0.000 description 8
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 102000004357 Transferases Human genes 0.000 description 8
- 108090000992 Transferases Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 229940009289 bifidobacterium lactis Drugs 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 229940072205 lactobacillus plantarum Drugs 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 208000018561 primary hyperoxaluria type 3 Diseases 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241000606125 Bacteroides Species 0.000 description 7
- 241000186016 Bifidobacterium bifidum Species 0.000 description 7
- 108010038519 Glyoxylate reductase Proteins 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 244000057717 Streptococcus lactis Species 0.000 description 7
- 235000014897 Streptococcus lactis Nutrition 0.000 description 7
- 230000001147 anti-toxic effect Effects 0.000 description 7
- 210000003578 bacterial chromosome Anatomy 0.000 description 7
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 7
- 229940004120 bifidobacterium infantis Drugs 0.000 description 7
- 108010028610 formyl-coenzyme A transferase Proteins 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 101100427060 Bacillus spizizenii (strain ATCC 23059 / NRRL B-14472 / W23) thyA1 gene Proteins 0.000 description 6
- 241000193171 Clostridium butyricum Species 0.000 description 6
- 108700010070 Codon Usage Proteins 0.000 description 6
- 101100153154 Escherichia phage T5 thy gene Proteins 0.000 description 6
- 108050002616 Formyl-CoA:oxalate CoA-transferases Proteins 0.000 description 6
- 108010000445 Glycerate dehydrogenase Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 108010059247 Hydroxypyruvate reductase Proteins 0.000 description 6
- 101100313751 Rickettsia conorii (strain ATCC VR-613 / Malish 7) thyX gene Proteins 0.000 description 6
- 108040000705 acetyl-CoA:oxalate CoA-transferases Proteins 0.000 description 6
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 101150072314 thyA gene Proteins 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 5
- 241001608472 Bifidobacterium longum Species 0.000 description 5
- 241001657508 Eggerthella lenta Species 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 5
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 5
- 244000199866 Lactobacillus casei Species 0.000 description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 description 5
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 5
- 241000186359 Mycobacterium Species 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 101150042295 arfA gene Proteins 0.000 description 5
- 229940009291 bifidobacterium longum Drugs 0.000 description 5
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 5
- 229940017800 lactobacillus casei Drugs 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 101150087557 omcB gene Proteins 0.000 description 5
- 101150115693 ompA gene Proteins 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 241000606124 Bacteroides fragilis Species 0.000 description 4
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 4
- 241000252867 Cupriavidus metallidurans Species 0.000 description 4
- 241000194033 Enterococcus Species 0.000 description 4
- 241000194032 Enterococcus faecalis Species 0.000 description 4
- 108091026922 FnrS RNA Proteins 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 101100082540 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) pcp gene Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 241000186604 Lactobacillus reuteri Species 0.000 description 4
- 241000194036 Lactococcus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 101100178822 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) htrA1 gene Proteins 0.000 description 4
- 229910002651 NO3 Inorganic materials 0.000 description 4
- 206010029148 Nephrolithiasis Diseases 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 101100277437 Rhizobium meliloti (strain 1021) degP1 gene Proteins 0.000 description 4
- 241000235070 Saccharomyces Species 0.000 description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000008238 biochemical pathway Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 101150018266 degP gene Proteins 0.000 description 4
- 101150083941 degS gene Proteins 0.000 description 4
- 235000018823 dietary intake Nutrition 0.000 description 4
- LZDSILRDTDCIQT-UHFFFAOYSA-N dinitrogen trioxide Chemical compound [O-][N+](=O)N=O LZDSILRDTDCIQT-UHFFFAOYSA-N 0.000 description 4
- 229940032049 enterococcus faecalis Drugs 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 229940001882 lactobacillus reuteri Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 101150074251 lpp gene Proteins 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 125000003431 oxalo group Chemical group 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 229960002181 saccharomyces boulardii Drugs 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 4
- 108010071258 4-hydroxy-2-oxoglutarate aldolase Proteins 0.000 description 3
- 101100162202 Aspergillus parasiticus (strain ATCC 56775 / NRRL 5862 / SRRC 143 / SU-1) aflF gene Proteins 0.000 description 3
- 101100203377 Bacillus subtilis (strain 168) slp gene Proteins 0.000 description 3
- 241001134770 Bifidobacterium animalis Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000193401 Clostridium acetobutylicum Species 0.000 description 3
- 241000193470 Clostridium sporogenes Species 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 101100242529 Drosophila melanogaster Pal2 gene Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000194031 Enterococcus faecium Species 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 108090000698 Formate Dehydrogenases Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 102100030648 Glyoxylate reductase/hydroxypyruvate reductase Human genes 0.000 description 3
- 101001010442 Homo sapiens Glyoxylate reductase/hydroxypyruvate reductase Proteins 0.000 description 3
- 208000000913 Kidney Calculi Diseases 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 101150012565 LRIT1 gene Proteins 0.000 description 3
- 241000186606 Lactobacillus gasseri Species 0.000 description 3
- 241000186605 Lactobacillus paracasei Species 0.000 description 3
- 101100477497 Mus musculus Shcbp1 gene Proteins 0.000 description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 3
- 108090000913 Nitrate Reductases Proteins 0.000 description 3
- 241000605937 Oxalobacter Species 0.000 description 3
- 241000350158 Prioria balsamifera Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000588777 Providencia rettgeri Species 0.000 description 3
- 241000607768 Shigella Species 0.000 description 3
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229940118852 bifidobacterium animalis Drugs 0.000 description 3
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical group [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000001925 catabolic effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 208000028208 end stage renal disease Diseases 0.000 description 3
- 201000000523 end stage renal failure Diseases 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- DCKSLNCVZHTEJK-UHFFFAOYSA-N formic acid;oxalic acid Chemical compound OC=O.OC(=O)C(O)=O DCKSLNCVZHTEJK-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 3
- 101150076456 norB gene Proteins 0.000 description 3
- 101150073640 ompF gene Proteins 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 101150077062 pal gene Proteins 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 101150061964 tolA gene Proteins 0.000 description 3
- 101150014665 tolB gene Proteins 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 2
- WXSKVKPSMAHCSG-UHFFFAOYSA-N 4-hydroxy-2-oxoglutaric acid Chemical compound OC(=O)C(O)CC(=O)C(O)=O WXSKVKPSMAHCSG-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 101150003270 Agxt gene Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000193749 Bacillus coagulans Species 0.000 description 2
- 101100404144 Bacillus subtilis (strain 168) nasD gene Proteins 0.000 description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 2
- 241000589173 Bradyrhizobium Species 0.000 description 2
- 241000589174 Bradyrhizobium japonicum Species 0.000 description 2
- 241001453380 Burkholderia Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108090000489 Carboxy-Lyases Proteins 0.000 description 2
- 102000004031 Carboxy-Lyases Human genes 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- RBNPOMFGQQGHHO-UWTATZPHSA-M D-glycerate Chemical compound OC[C@@H](O)C([O-])=O RBNPOMFGQQGHHO-UWTATZPHSA-M 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 101100465553 Dictyostelium discoideum psmB6 gene Proteins 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 241001302654 Escherichia coli Nissle 1917 Species 0.000 description 2
- 241000186394 Eubacterium Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101150071208 HOGA1 gene Proteins 0.000 description 2
- 101000861519 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Probable formate transporter Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 102000004317 Lyases Human genes 0.000 description 2
- 108090000856 Lyases Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 108050004064 Major facilitator superfamily Proteins 0.000 description 2
- 102000015841 Major facilitator superfamily Human genes 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 241000186367 Mycobacterium avium Species 0.000 description 2
- 241000186363 Mycobacterium kansasii Species 0.000 description 2
- 241000186362 Mycobacterium leprae Species 0.000 description 2
- 241000187480 Mycobacterium smegmatis Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 241000187917 Mycobacterium ulcerans Species 0.000 description 2
- 241000221960 Neurospora Species 0.000 description 2
- 241000221961 Neurospora crassa Species 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 108010068005 Oxalate decarboxylase Proteins 0.000 description 2
- 101000614295 Oxalobacter formigenes Oxalate:formate antiporter Proteins 0.000 description 2
- 206010049226 Oxalosis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000930992 Paraburkholderia fungorum Species 0.000 description 2
- 241001509383 Paraburkholderia xenovorans Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 101100169519 Pyrococcus abyssi (strain GE5 / Orsay) dapAL gene Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 241000232299 Ralstonia Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 241000190932 Rhodopseudomonas Species 0.000 description 2
- 241000190950 Rhodopseudomonas palustris Species 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 241001464942 Thauera Species 0.000 description 2
- 241000608961 Thauera aromatica Species 0.000 description 2
- 241000204667 Thermoplasma Species 0.000 description 2
- 241000489996 Thermoplasma volcanium Species 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 108010046179 Type VI Secretion Systems Proteins 0.000 description 2
- 241001147801 [Clostridium] scindens Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940054340 bacillus coagulans Drugs 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000005483 chronic intestinal vascular insufficiency Diseases 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 101150011371 dapA gene Proteins 0.000 description 2
- 101150000582 dapE gene Proteins 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- SXMOKYXNAPLNCW-GORZOVPNSA-N formyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SXMOKYXNAPLNCW-GORZOVPNSA-N 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000000173 nephrocalcinosis Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 101150044129 nirB gene Proteins 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000003891 oxalate salts Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 230000000858 peroxisomal effect Effects 0.000 description 2
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- 102100038837 2-Hydroxyacid oxidase 1 Human genes 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 241001233887 Ania Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100326957 Bacillus subtilis (strain 168) catD gene Proteins 0.000 description 1
- 101100290837 Bacillus subtilis (strain 168) metAA gene Proteins 0.000 description 1
- 101100076641 Bacillus subtilis (strain 168) metE gene Proteins 0.000 description 1
- 101100188971 Bacillus subtilis (strain 168) oxdC gene Proteins 0.000 description 1
- 101100478574 Bacillus subtilis (strain 168) ssuA gene Proteins 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241000003117 Bifidobacterium breve UCC2003 Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000510930 Brachyspira pilosicoli Species 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000863012 Caulobacter Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193167 Clostridium cochlearium Species 0.000 description 1
- 241001509499 Clostridium felsineum Species 0.000 description 1
- 241000530936 Clostridium novyi NT Species 0.000 description 1
- 241001147791 Clostridium paraputrificum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241001656801 Clostridium roseum Species 0.000 description 1
- 241000186528 Clostridium tertium Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000193452 Clostridium tyrobutyricum Species 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical group O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 108010073254 Colicins Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 101100498063 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) cysB gene Proteins 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101100012715 Escherichia coli (strain K12) frc gene Proteins 0.000 description 1
- 101100337717 Escherichia coli (strain K12) grcA gene Proteins 0.000 description 1
- 101100028306 Escherichia coli (strain K12) oxc gene Proteins 0.000 description 1
- 101100213163 Escherichia coli (strain K12) ydfU gene Proteins 0.000 description 1
- 101100213349 Escherichia coli (strain K12) ygbA gene Proteins 0.000 description 1
- 241000660147 Escherichia coli str. K-12 substr. MG1655 Species 0.000 description 1
- 101150099538 FNR gene Proteins 0.000 description 1
- MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical class [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100024977 Glutamine-tRNA ligase Human genes 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 101100508941 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) ppa gene Proteins 0.000 description 1
- 101100293613 Haloferax mediterranei (strain ATCC 33500 / DSM 1411 / JCM 8866 / NBRC 14739 / NCIMB 2177 / R-4) nasB gene Proteins 0.000 description 1
- 241000193159 Hathewaya histolytica Species 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 101100203896 Homo sapiens AGXT gene Proteins 0.000 description 1
- 101100285501 Homo sapiens HOGA1 gene Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108030002950 Oxalate CoA-transferases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000002389 Pouchitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000018819 Protein Translocation Systems Human genes 0.000 description 1
- 108700014910 Pseudomonas aeruginosa DNR Proteins 0.000 description 1
- 208000009527 Refractory anemia Diseases 0.000 description 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091006178 SLC26 Proteins 0.000 description 1
- 108091006503 SLC26A1 Proteins 0.000 description 1
- 108091006517 SLC26A6 Proteins 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241001468001 Salmonella virus SP6 Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101100370749 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) trpC1 gene Proteins 0.000 description 1
- 102000018509 Sulfate Transporters Human genes 0.000 description 1
- 101100241087 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) nrtP gene Proteins 0.000 description 1
- 101100245038 Synechocystis sp. (strain PCC 6803 / Kazusa) proA1 gene Proteins 0.000 description 1
- 101100132804 Thermus thermophilus narK1 gene Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010058153 Twin-Arginine-Translocation System Proteins 0.000 description 1
- 108010069584 Type III Secretion Systems Proteins 0.000 description 1
- 108010046504 Type IV Secretion Systems Proteins 0.000 description 1
- 108010050970 Type VII Secretion Systems Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 101150057540 aar gene Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 101150061301 ahpF gene Proteins 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000009604 anaerobic growth Effects 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 101150100261 aniA gene Proteins 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000025341 autosomal recessive disease Diseases 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001628 butyrogenic effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- PGFBRHFANBMLLX-UHFFFAOYSA-K calcium sodium dihydrogen phosphate carbonate Chemical compound [Na+].[Ca+2].OC([O-])=O.OP([O-])([O-])=O PGFBRHFANBMLLX-UHFFFAOYSA-K 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 101150111114 cysE gene Proteins 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 101150073654 dapB gene Proteins 0.000 description 1
- 101150064923 dapD gene Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 101150060377 flhD gene Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 101150077334 focA gene Proteins 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010064177 glutamine synthetase I Proteins 0.000 description 1
- 108010051239 glutaminyl-tRNA synthetase Proteins 0.000 description 1
- 101150097303 glyA gene Proteins 0.000 description 1
- 101150079604 glyA1 gene Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108010062584 glycollate oxidase Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 101150107068 gsiB gene Proteins 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 239000002271 gyrase inhibitor Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 101150107671 hisB gene Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 101150041770 hlyE gene Proteins 0.000 description 1
- 101150083365 hmp gene Proteins 0.000 description 1
- 101150089835 hmpA gene Proteins 0.000 description 1
- 101150099805 htpG gene Proteins 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 101150095957 ilvA gene Proteins 0.000 description 1
- 101150043028 ilvD gene Proteins 0.000 description 1
- 101150105723 ilvD1 gene Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 101150025049 leuB gene Proteins 0.000 description 1
- WQVJUBFKFCDYDQ-BBWFWOEESA-N leubethanol Natural products C1=C(C)C=C2[C@H]([C@H](CCC=C(C)C)C)CC[C@@H](C)C2=C1O WQVJUBFKFCDYDQ-BBWFWOEESA-N 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 101150033534 lysA gene Proteins 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- 101150060102 metA gene Proteins 0.000 description 1
- 101150086633 metAA gene Proteins 0.000 description 1
- 101150091110 metAS gene Proteins 0.000 description 1
- 101150003180 metB gene Proteins 0.000 description 1
- 101150117293 metC gene Proteins 0.000 description 1
- 101150043924 metXA gene Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 101150062306 narK gene Proteins 0.000 description 1
- 101150037810 narT gene Proteins 0.000 description 1
- 101150056725 narX gene Proteins 0.000 description 1
- 101150106215 ndh gene Proteins 0.000 description 1
- 230000008599 nitrosative stress Effects 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 101150021871 norC gene Proteins 0.000 description 1
- 101150055219 nrfA gene Proteins 0.000 description 1
- 101150029849 nsrR gene Proteins 0.000 description 1
- 101150110245 ompC gene Proteins 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 101150008884 osmY gene Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- MUBZPKHOEPUJKR-NJFSPNSNSA-N oxalic acid Chemical compound [14C](C(=O)O)(=O)O MUBZPKHOEPUJKR-NJFSPNSNSA-N 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 101150038927 pdhR gene Proteins 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 101150023849 pheA gene Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 101150004519 pilC gene Proteins 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 101150118057 proA gene Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 108010030416 proteoliposomes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 101150116440 pyrF gene Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 101150000850 thrC gene Proteins 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000005820 transferase reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 101150016309 trpC gene Proteins 0.000 description 1
- 101150083154 tyrA gene Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 101150046435 uraA gene Proteins 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 101150096946 ydfZ gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
- C12Y208/03—CoA-transferases (2.8.3)
- C12Y208/03016—Formyl-CoA transferase (2.8.3.16)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01002—Oxalate decarboxylase (4.1.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01008—Oxalyl-CoA decarboxylase (4.1.1.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
- C12Y602/01—Acid-Thiol Ligases (6.2.1)
- C12Y602/01008—Oxalate--CoA ligase (6.2.1.8)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960950P | 2020-01-14 | 2020-01-14 | |
| US202062993301P | 2020-03-23 | 2020-03-23 | |
| US202063028902P | 2020-05-22 | 2020-05-22 | |
| US202063065752P | 2020-08-14 | 2020-08-14 | |
| US202063089758P | 2020-10-09 | 2020-10-09 | |
| US202063091620P | 2020-10-14 | 2020-10-14 | |
| US202063111376P | 2020-11-09 | 2020-11-09 | |
| PCT/US2021/013401 WO2021146397A1 (en) | 2020-01-14 | 2021-01-14 | Bacteria engineered to treat disorders in which oxalate is detrimental |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL294710A true IL294710A (en) | 2022-09-01 |
Family
ID=76864711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL294710A IL294710A (en) | 2020-01-14 | 2021-01-14 | Bacteria engineered to treat disorders in which oxalate is detrimental |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230092431A1 (https=) |
| EP (1) | EP4090343A4 (https=) |
| JP (1) | JP2023511282A (https=) |
| CN (1) | CN115335066A (https=) |
| AU (1) | AU2021207879A1 (https=) |
| BR (1) | BR112022013867A2 (https=) |
| CA (1) | CA3167754A1 (https=) |
| IL (1) | IL294710A (https=) |
| WO (1) | WO2021146397A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3203975A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| WO2022204406A1 (en) * | 2021-03-24 | 2022-09-29 | Synlogic Operating Company, Inc. | Bacteria engineered to treat disorders in which oxalate is detrimental |
| CA3216359A1 (en) | 2021-04-07 | 2022-10-13 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| GB202402011D0 (en) | 2024-02-14 | 2024-03-27 | Snipr Biome Aps | A novel type of crispr/cas system |
| AU2024353375A1 (en) | 2023-09-29 | 2026-04-09 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1309427B1 (it) * | 1999-05-28 | 2002-01-23 | Mendes S U R L | Composizione dietetica o farmaceutica utile per la prevenzione o iltrattamento dell'iperossaluria e suo uso |
| WO2007070052A2 (en) * | 2005-12-14 | 2007-06-21 | Oxthera, Inc. | Pharmaceutical compositions and methods for treating or preventing oxalate-related disease |
| US9283252B2 (en) * | 2008-09-30 | 2016-03-15 | Meiji Co., Ltd. | Lactic acid bacterium having high oxalic acid decomposition ability |
| US11273184B2 (en) * | 2015-08-31 | 2022-03-15 | Synlogic Operating Company, Inc. | Bacteria engineered to treat disorders in which oxalate is detrimental |
| EP3468572B1 (en) * | 2016-06-13 | 2022-03-02 | OxThera Intellectual Property AB | Compositions and methods for the treatment or prevention of oxalate-related disorders |
| CN111655841A (zh) * | 2017-06-21 | 2020-09-11 | 同生运营公司 | 用于治疗紊乱的细菌 |
| JP2020527025A (ja) * | 2017-07-12 | 2020-09-03 | シンロジック オペレーティング カンパニー インコーポレイテッド | 腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物 |
| IT201800005355A1 (it) * | 2018-05-14 | 2019-11-14 | Lactobacillus amylovorus SGL 14: attività probiotiche e riduzione dell’ossalato enterico |
-
2021
- 2021-01-14 BR BR112022013867A patent/BR112022013867A2/pt not_active IP Right Cessation
- 2021-01-14 CN CN202180020940.5A patent/CN115335066A/zh active Pending
- 2021-01-14 US US17/792,030 patent/US20230092431A1/en not_active Abandoned
- 2021-01-14 JP JP2022542946A patent/JP2023511282A/ja active Pending
- 2021-01-14 EP EP21741375.6A patent/EP4090343A4/en not_active Withdrawn
- 2021-01-14 AU AU2021207879A patent/AU2021207879A1/en not_active Abandoned
- 2021-01-14 CA CA3167754A patent/CA3167754A1/en active Pending
- 2021-01-14 WO PCT/US2021/013401 patent/WO2021146397A1/en not_active Ceased
- 2021-01-14 IL IL294710A patent/IL294710A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022013867A2 (pt) | 2022-09-13 |
| WO2021146397A1 (en) | 2021-07-22 |
| EP4090343A4 (en) | 2024-02-14 |
| JP2023511282A (ja) | 2023-03-17 |
| US20230092431A1 (en) | 2023-03-23 |
| AU2021207879A1 (en) | 2022-09-08 |
| CA3167754A1 (en) | 2021-07-22 |
| CN115335066A (zh) | 2022-11-11 |
| EP4090343A1 (en) | 2022-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220233609A1 (en) | Bacteria engineered to treat disorders in which oxalate is detrimental | |
| JP7592777B2 (ja) | 高フェニルアラニン血症を低減させるように操作された細菌 | |
| JP7494345B2 (ja) | 高フェニルアラニン血症を低減させるように操作された細菌 | |
| US20230092431A1 (en) | Bacteria engineered to treat disorders in which oxalate is detrimental | |
| US20170216370A1 (en) | Bacteria engineered to treat disorders involving propionate catabolism | |
| WO2017123592A1 (en) | Bacteria engineered to treat disorders associated with bile salts | |
| WO2017075485A1 (en) | Bacteria engineered to treat disorders in which trimethylamine (tma) is detrimental | |
| WO2017023818A1 (en) | Bacteria engineered to treat disorders involving propionate catabolism | |
| US20240197843A1 (en) | Bacteria engineered to treat disorders in which oxalate is detrimental | |
| WO2024129974A1 (en) | Recombinant bacteria for use in the treatment of disorders in which oxalate is detrimental | |
| CN117083068A (zh) | 经工程化以治疗其中草酸盐有害的病症的细菌 |